Clinical Trials Browser

Recruiting × Radiation × Genitourinary × Clear all

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT06235697 2026-04-14

ASCENDE-SBRT

Phase 3 Recruiting

Prostatic Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04423211 2026-04-03

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Phase 3 Recruiting

Prostatic Neoplasms

NCT05946213 2026-04-03

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT06244004 2026-03-30

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT06171269 2026-03-04

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Phase NA Recruiting

Prostatic Neoplasms

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Recruiting

Wilms Tumor

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03861676 2026-02-13

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT06625034 2026-02-10

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT07202247 2026-02-04

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Phase 3 Recruiting

Prostatic Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Phase 2 Recruiting

Prostate Adenocarcinoma

NCT05805371 2025-11-19

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Phase 2 Recruiting

Oligometastatic Prostate Carcinoma

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT01492972 2025-09-04

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT04249154 2025-06-25

PROMPT

Phase 2 Recruiting

Prostatic Neoplasms